NCT05283226: An ongoing trial by NATCO Pharma Ltd.
This trial is ongoing. It must report results 6 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05283226 |
|---|---|
| Title | A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 30, 2022 |
| Completion date | June 30, 2025 |
| Required reporting date | June 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |